Instem’s Acquisition of Leading Clinical Trial Technology and Consulting Provider d-wise Represents Substantial Advancement of its Mission
PHILADELPHIA, PA – (BUSINESS WIRE) – March 22, 2021 - Instem, a leading provider of IT solutions and services to the global life sciences market, announced today that it has acquired clinical trial technology and consulting leader d-wise, Inc. (d-wise) as part of its mission to enable clients to bring their life enhancing products to market faster. The further consolidation of key application areas will help customers streamline and accelerate their research and development processes, while access to a broader range of data from across the R&D continuum will increase the power of future in silico modelling and prediction solutions.
April 20, 2020 - Please read our latest update on how we’re helping clients fight the COVID-19 pandemic.
March 1, 2021 - Instem’s Acquisition of Discovery Technology Solutions Provider, The Edge, Represents Another Advancement of its Mission in the Life Sciences
January 27, 2021 - High Demand for Target Safety Assessment Services and Computational Toxicology Solutions Continues Throughout Discovery and Nonclinical
December 10, 2020 - Technology-enabled service delivers fast, efficient, comprehensive in silico toxicology predictions
October 22, 2020 - Bi-weekly blog to provide best-practice insight, observations and opinions to help navigate the challenges and opportunities of SEND
Annual Conference of the British Toxicology Society
April 12 - 14, 2021
Presentation: Establishing standards for in silico toxicity prediction protocols
Speaker: Dr. Glenn Myatt, Vice President Informatics, Leadscope (an Instem company)
GTA Annual Meeting 2021
May 3 - 6, 2021
RAPS Euro Convergence 2021
May 10 - 12, 2021